Abstract
The use of immune checkpoint inhibitors in upper track gastrointestinal malignancies is a major and rapidly evolving field of research. As a result in the last 5 years a lot of data have emerged from randomized clinical trials and even more are expected in the future.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
